 |
Eurand's supplier responds to FDA on Zentase
Tuesday 6 January 2009
Eurand said its raw material supplier for the pancreatic enzyme replacement product (PEP) Zentase (EUR-1008; pancrealipase) has responded to US FDA questions on the pending NDA.
Latest News
Pfizer exercises right to develop Cytos's vaccines
Pfizer has exercised its option to acquire commercial licences for specific vaccines from Cytos Biotechnology.
Tuesday 6 January 2009
FDA user fee date for King's Embeda passes without action
The US FDA's review of King Pharmaceuticals' (formerly Alpharma's) Embeda, a modified-released formulation of morphine coupled with the opioid antagonist naltrexone, has been extended beyond the late December user fee date.
Tuesday 6 January 2009
Danish price freeze continues
Prescription drug prices in Denmark will not be allowed to rise until January 2010 after the health ministry and Lif, the pharmaceutical industry association, agreed to extend the two-year price-capping deal that they signed two years ago.
Tuesday 6 January 2009
France cuts clinical trial fees
Researchers in France no longer have to pay fees to register clinical trials with Afssaps, the national medicines regulator.
Tuesday 6 January 2009
More News
Most Read
- Roche snaps up more biotech firms
- 2008 Scrip Awards celebrate industry's achievements
- Omeros appoints David Mann to Board
- Yondelis to be filed for ovarian cancer after Phase III success
- Amgen's denosumab succeeds in key osteoporosis trial
- Elan and Wyeth's Alzheimer's hope fails to impress
- BMS makes $4.5 billion bid for ImClone Systems
Features & Analysis
MolMed reveals secret to IPO success
In a year in which the number of successful biotech IPOs fell to just three, it is hard to understand how and why even those few triumphant companies managed to raise funds in such harsh economic conditions. However, Dr Claudio Bordignon, the CEO of MolMed who oversaw the Italian biotech's €56.2 million IPO in March, recently told Scrip that the company's success came as a result of three simple factors...
Commentary - 5 January 2009
Scrip stock tracker - November 2008
November brought with it more turmoil on the financial markets. Some hoped that as we limped towards the end of 2008, the end of the beginning might be in sight. With many major economies now in recession, in this Stock Tracker for November US reporter Christopher Spillane throws some light on how these events were trickling down to the life sciences.
Stock tracker - November 2008
Japan pharma takes its place in the global market
How Japanese companies face new challenges will determine the future size and shape of their role within the global industry. Dr Michael Jones surveys changes over the past decade and analyses the current corporate and regulatory environment
Executive Briefing - Vol 1 No 10 December 2008
Senior managers need fresh skills and solid experience
Pharma’s development leaders need to have the capacity to fall in love with their molecules, and the courage to demand a divorce should the circumstances warrant it, say Dr Stevo Knezevic and Dr Peter Woods
Market Insight - 23 December 2008
More Analysis
Blog
Merck & Co underlines pharma’s resilience to recession
The news that grabbed the headlines last week was Merck & Co’s aim to lead generic biologics. As it stands, Merck could be the first US brand name drug company to enter the generic biologics market...
Read More
Posted 18/12/2008 15:59:45 PM
by Christopher Spillane,
Reporter
The 'truth drug'
The Indian authorities are reported to be using a so-called ‘truth drug’ on the man arrested on suspicion of involvement in the recent atrocities in Mumbai.
Read More
Posted 11/12/2008 17:12:00 PM
by Dr Peter Charlish,
Analyst
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
